Great for added energy and a metabolism boost
This is especially true for long-term semaglutide use
For more details, check out the link mentioned below: #EliLilly #orforglipron #Chinainvestment #oralobesitytreatment #type2diabetesdrug #obesitydrug #pharma #medicaldialogues To view or add a comment, sign in As obesity rates increase globally, dentistry is beginning to see its downstream effects, particularly in periodontal disease, caries risk, and systemic inflammation
Eli Lilly's FY2024 performance was extraordinary: total revenues of USD 45.0 billion, up 32% year-on-year, driven by Mounjaro (approximately USD 11.5 billion full-year, a more than 4 increase from 2023) and Zepbound (approximately USD 4.9 billion for its first full year of obesity indication sales, including the landmark Q4 figure of USD 1.9 billion)
"Dose adjustments are probably not required for simultaneous use of GLP1RAs with oral medications